The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO GI 2025 | Recent progress in immunotherapy-induced GI toxicity research
Yinghong Wang, MD, PhD, The University of Texas MD Anderson Cancer Center, Houston, TX, comments on the progress made in immunotherapy-induced upper and lower GI toxicity, highlighting the successful enrollment of patients in fecal transplantation trials and randomized infliximab, vedolizumab trials for immunotherapy-induced colitis, with expected trial closures within the next three months. Dr Wang also notes the upcoming publication of a second immunotherapy toxicity book featuring 60 cases from 14 academic centers globally, aiming to provide educational benefits to the public. This interview took place at the ASCO GI Cancers Symposium 2025 in San Francisco, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
